CN1660196A - Extractive of Chinese traditional medicine prepared from epimedium and drynaria, and method for producing preparation - Google Patents
Extractive of Chinese traditional medicine prepared from epimedium and drynaria, and method for producing preparation Download PDFInfo
- Publication number
- CN1660196A CN1660196A CN 200410061319 CN200410061319A CN1660196A CN 1660196 A CN1660196 A CN 1660196A CN 200410061319 CN200410061319 CN 200410061319 CN 200410061319 A CN200410061319 A CN 200410061319A CN 1660196 A CN1660196 A CN 1660196A
- Authority
- CN
- China
- Prior art keywords
- extract
- herba epimedii
- rhizoma drynariae
- chinese medicine
- aqueous alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 12
- 241000893536 Epimedium Species 0.000 title abstract description 4
- 235000018905 epimedium Nutrition 0.000 title abstract description 4
- 241001116742 Drynaria Species 0.000 title abstract description 3
- 238000004519 manufacturing process Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000011347 resin Substances 0.000 claims abstract description 8
- 229920005989 resin Polymers 0.000 claims abstract description 8
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 7
- 238000007670 refining Methods 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 210000000988 bone and bone Anatomy 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 210000003734 kidney Anatomy 0.000 claims description 7
- 229930003944 flavone Natural products 0.000 claims description 6
- 235000011949 flavones Nutrition 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 150000002213 flavones Chemical class 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 4
- 150000002215 flavonoids Chemical class 0.000 claims description 4
- 235000017173 flavonoids Nutrition 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims description 3
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims description 3
- 238000003811 acetone extraction Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 3
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims description 3
- 229930019673 naringin Natural products 0.000 claims description 3
- 229940052490 naringin Drugs 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 2
- 229940126678 chinese medicines Drugs 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 241000255789 Bombyx mori Species 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 238000011017 operating method Methods 0.000 claims 1
- 108010048734 sclerotin Proteins 0.000 claims 1
- 239000010902 straw Substances 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 238000000926 separation method Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 6
- 210000002997 osteoclast Anatomy 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000001582 osteoblastic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001480055 Quercus mongolica Species 0.000 description 2
- 206010039984 Senile osteoporosis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- -1 flavone glycosides Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- SVXJDTNFJXKATR-KQSLYFRASA-N Epimedin A Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(c2ccc(OC)cc2)Oc2c(C/C=C(\C)/C)c(O[C@H]3[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)cc(O)c2C1=O)[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 SVXJDTNFJXKATR-KQSLYFRASA-N 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000196124 Polypodiaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- SVXJDTNFJXKATR-UHFFFAOYSA-N hexandraside A Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 SVXJDTNFJXKATR-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating primary osteoporosis and climacteric syndrome is prepared from epimedium and fortune's drynaria rhizome through extracting in alcohol solution, macroreticular resin separation or extracting by ethyl acetate, and refining.
Description
The present invention relates to the preparation method by the extract and the preparation thereof of Herba Epimedii, Rhizoma Drynariae, wherein Herba Epimedii, Rhizoma Drynariae extract employing branch are put forward or are closed the method for putting forward and make.Extract the osteoporotic medicine of a kind of mixing treatment that obtains by aqueous alcohol or ethyl acetate, purpose is to provide a kind of active constituent content height, toxicity is low, taking dose is little, easy to use, is used for the product of osteoporosis and climacteric syndrome.
Medicine of the present invention is main effective site by Herba Epimedii, Rhizoma Drynariae total flavones.Mainly contain the total flavonoid composition that extracts from above two flavor Chinese crude drugs in this extract, its content is between 50%-95%
Background of invention
Osteoporosis is to reduce with the bone amount, and the micro structure of bone deteriorates to feature, causes the fragility of bone to increase a kind of general skeletal diseases with easy generation fracture.Climacteric syndrome, be the increase of people along with the age, the women causes that along with the decline of ovarian function neurological disorders, endocrine disturbance and dysbolismus are main climacteric syndrome, therefore this prescription is under the modern Chinese medicine guide of theory, preferred multiple kidney invigorating and YANG supporting, on the basis of treatment medicine for treating osteoporosis, a kind of little compound recipe that combines.
Herba Epimedii is a Berberidaceae plant Herba Epimedii, arrow leaf Herba Epimedii, the aerial parts of Herba Epimedii, mainly contain the epimedium flavone glycosides, epimedium flavone time glycosides, epimedin A, B, C etc., and contain potassium, calcium constituent, its function has kidney-replenishing, bone and muscle strengthening, wind-damp dispelling, be used for impotence and seminal emission, the muscles and bones flaccidity is soft, rheumatic arthralgia, numbness contracture, climacteric, hypertension etc., pharmacological action confirms that its effective ingredient of mainly treating diseases such as osteoporosis is mainly total flavonoids substance, in the experimentation and clinical practice of numerous treatment osteoporosis, its curative effect of Chinese medicine Herba Epimedii is generally acknowledged by everybody at present.Xie Hua etc. discover the bone formation rate that can obviously increase to Herba Epimedii etc., reduce bone resorption, bone loss due to the inhibition hydrocortisone, the long-pending increase of surface of bone, Herba Epimedii may be by promoting the proteinic synthetic effects such as promoting to do osteoblastic growth that reaches of osseous tissue, thereby the antagonism adrenocortical hormone decomposes osseous tissue protein, the synthetic effect that reduces of accelerated bone substrate has prevented the generation of osteoporosis.
Rhizoma Drynariae is the dry rhizome of fire hose section plant Mongolian oak Herba pteridii latiusculi, bitter in the mouth, warm in nature, return liver, kidney channel to have the kidney invigorating bone strengthening, promoting blood circulation and stopping pain, cure mainly lumbago due to renal deficiency, foot and knee flaccidity, tinnitus, deafness, toothache, chronic diarrhea, the enuresis, injury and bone fracture, the external treatment alopecia areata.Modern study proves that the Rhizoma Drynariae active component is based on Pericarpium Citri grandis glycoside flavanone kind composition.Yin Jun, Wang Dawei etc. have been studied, and the Rhizoma Drynariae ethanol extract is stronger to the proliferation function of WmR106 skeletonization like cell.And further definite its active part and active component, confirm that it has cell proliferation sample composition to exist to osteoblast, also containing has inhibiting composition to osteoclast propagation, mark is prosperous, Gao Zifan causes osteoporosis model to experimental group injection cortisone acetate, experimental group is irritated drynaria rhizome preparation every day, matched group is irritated the stomach tap water, the result shows the cortical bone of matched group and the demineralization substrate calcium in spongy bone density and the unit volume, the content of phosphorus and hydroxyproline, all be starkly lower than blank group, the every index of experimental group is higher than or apparently higher than matched group, illustrates that the osteomiosis complementary energy obviously suppresses the bone loss that glucocorticoid causes.Bone metabolism is finished jointly by bone resorption and bone formation.Sufferers of osteoporosis face generally is that bone resorption is greater than bone formation, be that osteoclast propagation and rate of differentiation are greater than osteoblastic proliferation and rate of differentiation, therefore, having the Rhizoma Drynariae that suppresses osteoclast propagation and stimulating osteoblast propagation simultaneously concurrently is conspicuous in the value of treatment senile osteoporosis.
Traditional Chinese medical herbal treatment osteoporosis (similar with the atrophic debility of bones disease of the traditional Chinese medical science) is historical to be of long duration, according in the theory of Chinese medical science " kidney storing essence master bone; the smart marrow of giving birth to; then bone marrow biochemistry is active; bone gets it and supports; otherwise; it is crisp easy to break bone to occur, diseases such as back arthralgia " Herba Epimedii in the side; Rhizoma Drynariae is the principal agent in the reinforcing the kidney to strengthen the bone Chinese medicine; little compound recipe is formed in therefore selected above two flavor Chinese medicine passing ratios screenings; at present owing to the reason that causes senile osteoporosis is many-sided; mechanism still imperfectly understands; but the old people since in the body sex hormone level descend, what cause that the osteoclast activity increase finally causes osteoporosis is its major reason, use chemical drugs treatment toxic and side effects big, and reinforcing the kidney to strengthen the bone class Chinese medicine and compound recipe thereof has the effect of parahormone sample, and can suppress osteoclast, to promote osteoblastic generation, bone formation is increased simultaneously, demonstrate the bright prospect of Chinese herb prevention climacteric syndrome and osteoporosis symptom.Also does not form at present by two flavor Chinese medicines, treatment osteoporosis effective parts formulation listing, so and invent this medicine.
Summary of the invention
The further main purpose of the present invention provides the compositions that the composition of the effective therapeutical effect that provides promptly is provided a kind of like this therapeutic combination, they are that Herba Epimedii extract and Rhizoma Drynariae extract branch are carried or closed and propose ratio combination, another technical problem of the present invention has provided and has a kind ofly prepared the method for these stable extracts and the preparation of drug combination that contains this stable extract method is provided, and wherein the amount of the icariin in the said composition, naringin also keeps stable.
According to the extract of these technical problems of the present invention with claim 1-6, with the method for claim 7-8, and claim drug regimen method and dosage form, relevant issues solve.
The preferred embodiment that the present invention prepares Herba Epimedii, Rhizoma Drynariae stable extract method has following steps;
1; With Herba Epimedii, Rhizoma Drynariae, water, aqueous alcohol, methanol, acetone extraction obtain extracting solution.
2; Use vacuum or other optional concentrator to concentrate
3; Wherein make water, methanol, aqueous alcohol carry out the dilution of above concentrated solution, centrifugal
4; With the polystyrene macroporous resin purification is carried out in Herba Epimedii, the active ingredient of Rhizoma Drynariae total flavonoid, and use degree of passing eluting separates, drying obtains extract.
5; With aqueous alcohol or ethyl acetate Herba Epimedii, Rhizoma Drynariae branch are carried or closed and carry thing and make with extra care, and concentrate, obtain the higher extract of content with vacuum and optional miscellaneous equipment.
6; Reach optional miscellaneous equipment drying with vacuum or spray drying and obtain qualified extract.
The specific embodiment
Preferred realization method of the present invention is; Chinese medicine extract as claimed in claim 2, Herba Epimedii, Rhizoma Drynariae weight proportion ratio are 4: 1～6, the Herba Epimedii ratio also can be 1～4.
Be used for claim 3, (1) with aqueous alcohol or acetone extraction Herba Epimedii branch and leaf, Rhizoma Drynariae rhizome position; Aqueous alcohol can be ethanol or methanol;
Be used for claim 3, (2) filter this extracting solution, and use vacuum concentration equipment to concentrate, reclaim solvent;
Be used for claim 3, (3) water or aqueous alcohol mixture diluted step (2), and its centrifugal slagging-off is obtained centrifugal liquid.Aqueous alcohol can be ethanol or methanol;
Being used for claim 3, (4), that gained centrifugal liquid is crossed the polystyrene type macroporous resin is refining, and uses degree of passing eluting.Selected range of resin can be silica gel, polyamide, macroporous adsorbent resin, be the best with the polystyrene type macroporous resin;
Be used for claim 3, (5) (4) resultant eluent is concentrated into thick paste and dry, and drying mode is optional; Drying mode can be lyophilization, vacuum drying, spray drying;
Be used for claim 3, (6) with (5) extract obtained can be solvent dissolving or with ethyl acetate extraction and refining with aquiferous ethanol, and solvent is reclaimed in the evaporation of the temperature about 40-80 ℃; Aqueous alcohol can be ethanol or methanol, is the best with ethanol, ethyl acetate;
Be used for claim 3, (7) with the gained extract dry, become optional powdered extract or granule; Be meant with extract dry to become extract powder or add adjuvant to make granule and fine powder.
Be used for the described extract of claim 6, it contains the total flavones (in icariin and naringin) of 10-90% (weight).
The method of the above-mentioned extraction Herba Epimedii of the present invention, Rhizoma Drynariae total flavones adopts kind Korea Herba Epimedii, arrow leaf Herba Epimedii or the pubescence Herba Epimedii of pharmacopeia regulation, and Rhizoma Drynariae adopts the dry rhizome of Polypodiaceae plant Mongolian oak Herba pteridii latiusculi.After obtaining qualified extract.And the implementation column of being correlated with prepares implementation, and he comprises relevant dosage forms such as ordinary tablet, capsule, dispersible tablet and soft capsule.
Embodiment 1 preparation capsule
Herba Epimedii extract 10g
Rhizoma Drynariae extract 2.5g
Starch 3g
Dextrin 1.5g
Magnesium stearate 0.1g
Medicinal alcohol 2-3ml
Embodiment 2 preparation conventional tablet and coatings
Herba Epimedii extract 10g
Rhizoma Drynariae extract 2.5g
Celluloasun Microcrystallisatum 8g
Starch Sodium 2g
Starch 3g
Magnesium stearate 0.2g
Coating powder 1g
Embodiment 3 preparation dispersible tablets
Herba Epimedii extract 10g
Rhizoma Drynariae extract 2.5g
Celluloasun Microcrystallisatum 8g
Starch Sodium 2g
Polyvinylpyrrolidone 1g
Micropowder silica gel 0.5g
Medicinal alcohol 3ml
Embodiment 4 preparation soft capsules
Herba Epimedii extract 10g
Rhizoma Drynariae extract 2.5g
Soybean oil 10ml
Polyethylene Glycol 2ml
Glycerol 2ml
Gelatin 8g
Purified water 3ml
Claims (9)
1. one kind is used to prepare the Chinese medicine extract for the treatment of constitutional sclerotin vegetables pine, climacteric syndrome medicament.This extract is made up of Herba Epimedii, Rhizoma Drynariae two flavor Chinese medicines.
2. Chinese medicine extract as claimed in claim 1, wherein Herba Epimedii, Rhizoma Drynariae part by weight proportioning are 4: 1～6.
3. as the preparation method of claim 1 described Chinese medicine extract, its operating procedure is
(1) with aqueous alcohol or acetone extraction Herba Epimedii branch and leaf, Rhizoma Drynariae rhizome position.
(2) filter this extracting solution, and use vacuum concentration equipment to concentrate, reclaim solvent.
(3) water or aqueous alcohol mixture diluted step (2), and its centrifugal slagging-off obtained centrifugal liquid.
(4) gained centrifugal liquid is crossed the polystyrene type macroporous resin and made with extra care, and use degree of passing eluting.
(5) (4) resultant eluent is concentrated into thick paste and dry, and drying mode is optional.
(6) with (5) extract obtained can be solvent dissolving or with ethyl acetate extraction and refining with aquiferous ethanol, and solvent is reclaimed in the evaporation of the temperature about 40-80 ℃;
(7), become optional powdered extract or granule with the gained extract dry.
4. method according to claim 3, wherein aqueous alcohol comprises that methanol, ethanol carry out step (1), extract (3).
5. can be D101 according to the described step of claim 3 (4) with the polystyrene type macroporous resin, DM130, XAD-16 etc. make with extra care Herba Epimedii, Rhizoma Drynariae total flavonoid effective ingredient.
6. according to the described step of claim 3 (6) Herba Epimedii, Rhizoma Drynariae are closed that to carry thing refining, wherein use methanol, ethanol, ethyl acetate.
7. according to the described extract of claim 6, it contains the total flavones (in icariin and naringin) of 10-95% (weight).
8. contain 7 the combined extracts of having the right and make composition of active components.
The extract of claim 8 preparation be the kidney invigorating, bone strengthening, strong muscle, pain relieving, be used for primary osteoporosis, climacteric syndrome, the sick aspect of cardiovascular a small bundle of straw, etc. for silkworms to spin cocoons on purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100613191A CN1331484C (en) | 2004-12-13 | 2004-12-13 | Extractive of Chinese traditional medicine prepared from epimedium and drynaria, and method for producing preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100613191A CN1331484C (en) | 2004-12-13 | 2004-12-13 | Extractive of Chinese traditional medicine prepared from epimedium and drynaria, and method for producing preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1660196A true CN1660196A (en) | 2005-08-31 |
| CN1331484C CN1331484C (en) | 2007-08-15 |
Family
ID=35009934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100613191A Expired - Fee Related CN1331484C (en) | 2004-12-13 | 2004-12-13 | Extractive of Chinese traditional medicine prepared from epimedium and drynaria, and method for producing preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1331484C (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579390B (en) * | 2008-05-15 | 2011-07-20 | 北京北大维信生物科技有限公司 | Medicinal dripping pill for treating osteoporosis |
| CN101780132B (en) * | 2009-01-17 | 2012-03-07 | 毕力夫 | Mongolian medicine for treating osteoporosis and preparation method thereof |
| CN102716233A (en) * | 2012-05-18 | 2012-10-10 | 北京师范大学 | Flavonoids extract containing naringin and application thereof |
| CN103251671A (en) * | 2012-12-28 | 2013-08-21 | 北京中研同仁堂医药研发有限公司 | Traditional Chinese medicine containing composition for increasing bone mineral density and preparation method thereof |
| CN104224888A (en) * | 2014-09-03 | 2014-12-24 | 上海焦点生物技术有限公司 | Traditional Chinese medicinal composition used for strengthening bone |
| CN104666394A (en) * | 2014-09-24 | 2015-06-03 | 普正药业股份有限公司 | Eucommia product having health protection efficacy on osteoporosis and preparation method of eucommia product |
| CN107184657A (en) * | 2016-03-15 | 2017-09-22 | 上海中医药大学附属龙华医院 | It is a kind of to treat compound Chinese medicinal preparation of primary osteoporosis and preparation method thereof |
| CN107320524A (en) * | 2017-06-30 | 2017-11-07 | 北京甄和利康生物科技有限公司 | A kind of pharmaceutical composition for being used to preventing and/or treating perimenopausal syndrome |
| CN108095074A (en) * | 2017-12-12 | 2018-06-01 | 浙江海洋大学 | A kind of tuna fish-bone health food of auxiliary treatment osteoporosis and preparation method thereof |
| CN111904992A (en) * | 2020-07-09 | 2020-11-10 | 华中科技大学鄂州工业技术研究院 | Composition for regulating intestinal flora of people with estrogen deficiency after climacteric period and preparation method thereof |
| CN113332338A (en) * | 2021-05-21 | 2021-09-03 | 陆华 | Pharmaceutical composition for warming kidney and tonifying yang |
| CN113533563A (en) * | 2021-07-07 | 2021-10-22 | 健民药业集团股份有限公司 | Method for simultaneously detecting contents of four components of liver-soothing, stomach-harmonizing and pain-relieving traditional Chinese medicine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1128625A (en) * | 1995-12-01 | 1996-08-14 | 王群 | Nutrition and medicinal type corn or carrot instant food, mfg. method thereof |
| CN1498629A (en) * | 2002-11-11 | 2004-05-26 | 刘香斌 | Chinese traditional medicine for treating osteoporosis and its prepn. method |
-
2004
- 2004-12-13 CN CNB2004100613191A patent/CN1331484C/en not_active Expired - Fee Related
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579390B (en) * | 2008-05-15 | 2011-07-20 | 北京北大维信生物科技有限公司 | Medicinal dripping pill for treating osteoporosis |
| CN101780132B (en) * | 2009-01-17 | 2012-03-07 | 毕力夫 | Mongolian medicine for treating osteoporosis and preparation method thereof |
| CN102716233A (en) * | 2012-05-18 | 2012-10-10 | 北京师范大学 | Flavonoids extract containing naringin and application thereof |
| CN103251671B (en) * | 2012-12-28 | 2015-11-18 | 北京中研同仁堂医药研发有限公司 | A kind of composition and method of making the same containing Chinese medicine increasing bone density |
| CN103251671A (en) * | 2012-12-28 | 2013-08-21 | 北京中研同仁堂医药研发有限公司 | Traditional Chinese medicine containing composition for increasing bone mineral density and preparation method thereof |
| CN104224888A (en) * | 2014-09-03 | 2014-12-24 | 上海焦点生物技术有限公司 | Traditional Chinese medicinal composition used for strengthening bone |
| CN104666394A (en) * | 2014-09-24 | 2015-06-03 | 普正药业股份有限公司 | Eucommia product having health protection efficacy on osteoporosis and preparation method of eucommia product |
| CN107184657A (en) * | 2016-03-15 | 2017-09-22 | 上海中医药大学附属龙华医院 | It is a kind of to treat compound Chinese medicinal preparation of primary osteoporosis and preparation method thereof |
| CN107320524A (en) * | 2017-06-30 | 2017-11-07 | 北京甄和利康生物科技有限公司 | A kind of pharmaceutical composition for being used to preventing and/or treating perimenopausal syndrome |
| CN108095074A (en) * | 2017-12-12 | 2018-06-01 | 浙江海洋大学 | A kind of tuna fish-bone health food of auxiliary treatment osteoporosis and preparation method thereof |
| CN108095074B (en) * | 2017-12-12 | 2021-02-02 | 浙江海洋大学 | Tuna fishbone health food for adjuvant treatment of osteoporosis and preparation method thereof |
| CN111904992A (en) * | 2020-07-09 | 2020-11-10 | 华中科技大学鄂州工业技术研究院 | Composition for regulating intestinal flora of people with estrogen deficiency after climacteric period and preparation method thereof |
| CN113332338A (en) * | 2021-05-21 | 2021-09-03 | 陆华 | Pharmaceutical composition for warming kidney and tonifying yang |
| CN113533563A (en) * | 2021-07-07 | 2021-10-22 | 健民药业集团股份有限公司 | Method for simultaneously detecting contents of four components of liver-soothing, stomach-harmonizing and pain-relieving traditional Chinese medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1331484C (en) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101612362B (en) | Complex preparation for regulating lipid and preventing and curing heart cerebrovascular diseases and preparation method thereof | |
| CN1331484C (en) | Extractive of Chinese traditional medicine prepared from epimedium and drynaria, and method for producing preparation | |
| Singh et al. | Orthobiologics with phytobioactive cues: A paradigm in bone regeneration | |
| CN1857664A (en) | Apoplexy treating preparation and its preparing process | |
| CN1857584A (en) | Hypertension treating Chinese medicine preparation | |
| CN1927240A (en) | Traditional Chinese medicine mask composition for depigmenting | |
| CN1840162A (en) | Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use | |
| CN1422622A (en) | Herba-Epimedii extract for treating prostatic hyerplasia and use in preparing medicine | |
| CN1060657C (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| RU2408383C1 (en) | Composition with antineoplastic and adaptogenic activity (versions) and based drug (versions) | |
| CN102058651B (en) | Medical composition for preventing and treating osteoporosis | |
| CN101040889A (en) | Traditional Chinese medicinal prepns. for treating osteoporosis | |
| CN1616076A (en) | Medicine for treating cardiocerebral vascular system disease and blood supply deficiency, medicine preparing method and preparation | |
| CN1440804A (en) | Antilipemic Chinese medicine | |
| CN1883679A (en) | Medicine for treating pulmonary tuberculosis | |
| CN1344558A (en) | Bone invigorating composition containing yak bone and its prepn | |
| CN1213762C (en) | Medicine for invigorating kidney, promoting blood circulation and promoting skeleton formation and its prepn | |
| CN1682788A (en) | Shutongfang for killing pain and its preparation and use | |
| CN1903244A (en) | Traditional Chinese medicine composition for treating sexual disorders | |
| CN1253179C (en) | Drug for treating ischemic necrosis of femoral head | |
| CN1115663A (en) | Medicine for curing hypertension | |
| CN1457806A (en) | Medicine for curing primary carcinoma of liver and its preparing method | |
| CN1205989C (en) | Medicine composition for treating ischemic necrosis of femur head and preparing process thereof | |
| CN1278698C (en) | Freeze dried injection of seeding of autumnal sowthistle-leaf ixeris and preparation method thereof | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WUHAN JIANMIN PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER OWNER: JIANMIN TRADITIONAL CHINESE MEDICINE ENGINEERING CO., LTD., WUHAN Effective date: 20111114 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20111114 Address after: 430052, 484 parrot Avenue, Hanyang District, Hubei, Wuhan Patentee after: Wuhan Jianmin Pharmaceutical Group Co.,Ltd. Address before: 430052, 484 parrot Avenue, Hanyang District, Hubei, Wuhan Patentee before: Wuhan Jianmin Traditional Chinese Pharmacy Engineering Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 430052, 484 parrot Avenue, Hanyang District, Hubei, Wuhan Patentee after: JIANMIN PHARMACEUTICAL GROUPS Corp.,Ltd. Address before: 430052, 484 parrot Avenue, Hanyang District, Hubei, Wuhan Patentee before: Wuhan Jianmin Pharmaceutical Group Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070815 Termination date: 20211213 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |